Erik Ekman Appointed New CEO in Bluefish
ERIK EKMAN IS APPOINTED NEW CEO FOR BLUEFISH PHARMACEUTICALS AB
Erik Ekman becomes the new CEO of Bluefish Pharmaceuticals. Erik will take up the position of CEO during the spring 2022 since Berit Lindholm has announced to the Board that she is leaving Bluefish Pharmaceuticals joining a non-competitive organisation.
Erik Ekman holds the COO position in the company since the last four years. Erik has a solid experience in the pharmaceutical industry and has previously held various roles in both AstraZeneca and Cambrex. Erik is a passionate and experienced leader who will be able to lead the company through the next growth phase.
Erik and Berit will continue in their roles until a successor to the COO post has been recruited.
- Bluefish Pharmaceuticals is on an exciting journey and with Erik’s broad competence and experience, he is the right leader for the CEO position. Erik has been involved in establishing the company's current strategy and has a good understanding of both Bluefish Pharmaceuticals and the pharmaceutical industry in general, says Gunilla Spongh, Chairman of the Board of Bluefish Pharmaceuticals AB.
I would also like to take this opportunity to thank Berit for the work she has done for the company, first as COO and then as CEO. She has successfully led and developed Bluefish Pharmaceuticals and is suggested to be part of the company’s board of directors. Berit will be able to continue to contribute to the company's future development, says Gunilla Spongh, Chairman of the Board of Bluefish Pharmaceuticals AB.
- It’s with great pleasure and humbleness that I take over as the CEO after Berit. Bluefish has a strong ambition to develop and grow and it is my ambition to continue this expansion of the company in the same spirit. I look forward to continuing our exciting journey together with the Bluefish team and our partners.
- I have been the CEO of Bluefish Pharmaceuticals for five years and we have had a fantastic journey. I am pleased with what we have achieved together during my seven years in Bluefish. I am also very proud of our accomplishments and results, and it is with confidence I hand over to Erik to continue this journey, says Berit Lindholm.
For more information contact:
Berit Lindholm, CEO, tel. 070-915 41 92
Gunilla Spongh, Chairman of the Board, tel. 070-935 25 33
Gerald Engstöm, CEO of Färna Invest, tel. 070-519 00 01
Bluefish Pharmaceuticals in brief:
Founded in Sweden in 2005, with its long tradition of industrial entrepreneurship, Bluefish Pharmaceuticals has become one of the most progressive Swedish pharmaceutical companies for generic products. The company focuses exclusively on development and sale of generic drugs. At Bluefish, we strive to make quality medicines accessible to more people. We create value in the full pharmaceutical value chain from developing to successfully marketing generic pharmaceuticals and we take pride in doing this in an innovative, responsible and cost-efficient way. The product portfolio consists of about 80 products and is growing. Bluefish currently conducts operations in 13 countries in Europe and, over the next few years, will also expand outside Europe with the aim of becoming a global player. The company has its own development laboratory in Bangalore where we develop our own generic products.
www.bluefishpharma.com
For more information, contact
Berit Lindholm, CEO Bluefish Pharmaceuticals
Tel. 46 8 519 116 00
Email: berit.lindholm@bluefishpharma.com
About Bluefish Pharmaceuticals
Bluefish has undergone significant international expansion since the company was founded in 2005. Bluefish focuses on the development, manufacture and sale of generic pharmaceuticals. The company conducts marketing operations in a large number of European markets and is expanding into territories outside Europe. The product portfolio consists of a total of approximately 80 products and is growing.